For decades, researchers have recognized the enormous potential of exosomes but it is only in recent years that companies are seeing some success in developing technologies to engineer exosomes with predictable and reproducible properties to be loaded with therapeutic molecules and directed at specific target cells. The industry is working to develop a commercially scalable, efficient, and reproducible manufacturing process for this new class of biotherapeutics, and DPS has been privileged to design facilities to support clients at the forefront of these new processes.